{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:03:31Z","timestamp":1778839411058,"version":"3.51.4"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:00:00Z","timestamp":1665532800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Cardiogenic shock (CS) is a life-threatening condition due to primary cardiac dysfunction. First-line therapy involves drug administration (including inotropes and\/or vasopressors) up to mechanical circulatory support. Tachycardia is a frequent compensatory mechanism in response to hypotension and low cardiac output or a side effect related to inotropic drugs. Ivabradine selectively acts on the IKf channel in the sinoatrial node to reduce sinus heart rate without affecting inotropism. Its use, in small non-randomized series of patients with CS without mechanical circulatory support, was safe and well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We present the use of ivabradine in six patients with CS undertaking veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and a matched cohort of selected patients with similar features who did not receive ivabradine. Data regarding haemodynamic and echocardiographic monitoring, oxygenation, renal function, mechanical circulatory support, inotropes, and vasopressors doses were collected before (t0), at 12 (t1), 24 (t2), and 48 (t3) h after ivabradine administration. Ivabradine administration led to a significant heart rate reduction of 20.83 [95% confidence interval (CI) \u221227.2 to \u221214.4] b.p.m. (&amp;lt;0.01). Echo-derived left ventricular native stroke volume (SV) significantly increased by +7.83 (95% CI 4.74\u201310.93) mL (P &amp;lt; 0.001) with a parallel reduction of VA-ECMO support [\u2212170 (95% CI \u2212225.05 to \u2212114.95)]. Noradrenaline was down-titrated over the observation period in all patients (P = 0.016).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A significant reduction in heart rate was observed after ivabradine administration. This was associated with a native ventricular SV improvement allowing the reduction of extracorporeal flow support and vasopressors administration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuac133","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T20:25:20Z","timestamp":1665519920000},"page":"916-921","source":"Crossref","is-referenced-by-count":9,"title":["Heart rate control and haemodynamic improvement with ivabradine in cardiogenic shock patient on mechanical circulatory support"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-3642","authenticated-orcid":false,"given":"Costanza N J","family":"Colombo","sequence":"first","affiliation":[{"name":"Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS , Viale Camillo Golgi, 19, Pavia 27100 , Italy"},{"name":"Experimental Medicine, University of Pavia , Via Alessandro Brambilla, 74, Pavia 27100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-591X","authenticated-orcid":false,"given":"Valentino","family":"Dammassa","sequence":"additional","affiliation":[{"name":"Experimental Medicine, University of Pavia , Via Alessandro Brambilla, 74, Pavia 27100 , Italy"},{"name":"Adult Intensive Care Unit, Royal Brompton Hospital , Sydney St, London SW3 6NP , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Klersy","sequence":"additional","affiliation":[{"name":"Service of Clinical Epidemiology & Biometry, Fondazione IRCCS Policlinico San Matteo , Viale Camillo Golgi, 19, Pavia 27100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Camporotondo","sequence":"additional","affiliation":[{"name":"Coronary Care Unit and Laboratory of Clinical and Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo , Viale Camillo Golgi, 19, Pavia 27100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Department of Surgical, Pediatric, and Diagnostic Sciences, University of Pavia , Viale Golgi 19, Pavia 27100 , Italy"},{"name":"Department of Cardiac Surgery, Fondazione IRCCS Policlinico San Matteo , Viale Camillo Golgi, 19, Pavia 27100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Mojoli","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS , Viale Camillo Golgi, 19, Pavia 27100 , Italy"},{"name":"Department of Surgical, Pediatric, and Diagnostic Sciences, University of Pavia , Viale Golgi 19, Pavia 27100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-5138","authenticated-orcid":false,"given":"Guido","family":"Tavazzi","sequence":"additional","affiliation":[{"name":"Anesthesia and Intensive Care, Fondazione Policlinico San Matteo Hospital IRCCS , Viale Camillo Golgi, 19, Pavia 27100 , Italy"},{"name":"Department of Surgical, Pediatric, and Diagnostic Sciences, University of Pavia , Viale Golgi 19, Pavia 27100 , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"key":"2022122716311985900_zuac133-B1","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/ejhf.1922","article-title":"Epidemiology, pathophysiology and contemporary management of cardiogenic shock\u2014a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Chioncel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022122716311985900_zuac133-B2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers","volume":"64","author":"Ragueneau","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"2022122716311985900_zuac133-B3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ehf2.12499","article-title":"Initiation of ivabradine in cardiogenic shock","volume":"6","author":"Chiu","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2022122716311985900_zuac133-B4","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jacc.2022.01.018","article-title":"SCAI SHOCK stage classification expert consensus update: a review and incorporation of validation studies: this statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021","volume":"79","author":"Naidu","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2022122716311985900_zuac133-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the American Society of Echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"2022122716311985900_zuac133-B6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacc.2004.03.060","article-title":"Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry","volume":"44","author":"Fincke","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022122716311985900_zuac133-B7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2048872613489305","article-title":"Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study","volume":"2","author":"Steg","year":"2013","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2022122716311985900_zuac133-B8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007744","article-title":"When sinus tachycardia becomes too much: negative effects of excessive upright tachycardia on cardiac output in vasovagal syncope, postural tachycardia syndrome, and inappropriate sinus tachycardia","volume":"13","author":"Stewart","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2022122716311985900_zuac133-B9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"2022122716311985900_zuac133-B10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2022122716311985900_zuac133-B11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jacc.2007.04.079","article-title":"Resting heart rate in cardiovascular disease","volume":"50","author":"Fox","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022122716311985900_zuac133-B12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial","volume":"310","author":"Morelli","year":"2013","journal-title":"JAMA"},{"key":"2022122716311985900_zuac133-B13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","article-title":"Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure","volume":"10","author":"De Ferrari","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2022122716311985900_zuac133-B14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0310057X211009913","article-title":"Effectiveness of enteral ivabradine for heart rate control in septic shock: a randomised controlled trial","volume":"49","author":"Datta","year":"2021","journal-title":"Anaesth Intensive Care"},{"key":"2022122716311985900_zuac133-B15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/SHK.0000000000000992","article-title":"Reducing elevated heart rates in patients with multiple organ dysfunction syndrome with the If (funny channel current) inhibitor ivabradine","volume":"49","author":"Nuding","year":"2018","journal-title":"Shock"},{"key":"2022122716311985900_zuac133-B16","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijcard.2014.07.093","article-title":"Hemodynamic effects of ivabradine in addition to dobutamine in patients with severe systolic dysfunction","volume":"176","author":"Gallet","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022122716311985900_zuac133-B17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13054-018-2124-8","article-title":"Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial","volume":"22","author":"Nguyen","year":"2018","journal-title":"Crit Care"}],"container-title":["European Heart Journal. Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuac133\/46451251\/zuac133.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/11\/12\/916\/48423633\/zuac133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/11\/12\/916\/48423633\/zuac133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T16:42:50Z","timestamp":1672159370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/11\/12\/916\/6759141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuac133","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,10,12]]}}}